Published in PLoS One on December 20, 2013
RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferation. Oncotarget (2016) 0.78
The extracellular interactome of the human adenovirus family reveals diverse strategies for immunomodulation. Nat Commun (2016) 0.76
The expression of the hepatocyte SLAMF3 (CD229) receptor enhances the hepatitis C virus infection. PLoS One (2014) 0.76
Hepatocyte SLAMF3 reduced specifically the multidrugs resistance protein MRP-1 and increases HCC cells sensitization to anti-cancer drugs. Oncotarget (2016) 0.75
Autophagy in the pathogenesis of disease. Cell (2008) 34.68
Hepatocellular carcinoma. Lancet (2003) 22.54
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell (2006) 10.29
Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol (2005) 9.00
Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell (2005) 7.75
The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene (2003) 7.41
The JNK signal transduction pathway. Curr Opin Cell Biol (2007) 5.86
Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer (2008) 5.35
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology (2006) 3.95
Regulation of cancer cell motility through actin reorganization. Cancer Sci (2005) 3.87
Bcl-2 family proteins and cancer. Oncogene (2008) 3.42
Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor beta 1. Proc Natl Acad Sci U S A (1992) 2.54
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nat Rev Immunol (2003) 2.26
Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest (2008) 2.26
Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc Natl Acad Sci U S A (2005) 2.23
Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis (2005) 2.18
Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology (2000) 2.15
mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res (2004) 2.14
Immune pathogenesis of hepatocellular carcinoma. J Exp Med (1998) 2.11
Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology (1998) 1.97
Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene (2006) 1.92
Binding of SAP SH2 domain to FynT SH3 domain reveals a novel mechanism of receptor signalling in immune regulation. Nat Cell Biol (2003) 1.92
Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood (2008) 1.85
Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol (2005) 1.77
Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis (2009) 1.72
Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol (2007) 1.71
Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative gene product. Nat Immunol (2001) 1.71
Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cells. Nat Immunol (2009) 1.55
Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology (2001) 1.46
Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression. Cancer Res (2006) 1.42
Ly9 (CD229)-deficient mice exhibit T cell defects yet do not share several phenotypic characteristics associated with SLAM- and SAP-deficient mice. J Immunol (2006) 1.36
Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology (2000) 1.35
Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene (2006) 1.34
Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. Curr Med Chem Anticancer Agents (2005) 1.32
Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer (2003) 1.32
Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Hum Pathol (2001) 1.27
An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol (2004) 1.26
Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance. World J Gastroenterol (2001) 1.20
SLAM-family receptors: immune regulators with or without SAP-family adaptors. Cold Spring Harb Perspect Biol (2010) 1.19
Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep (2006) 1.14
PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma. Cancer Res (2008) 1.13
CD84 functions as a homophilic adhesion molecule and enhances IFN-gamma secretion: adhesion is mediated by Ig-like domain 1. J Immunol (2001) 1.13
Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res (2004) 1.12
BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma. Mol Cancer Res (2010) 1.00
Importance and mechanism of 'switch' function of SAP family adapters. Immunol Rev (2009) 0.98
Identification of Grb2 as a novel binding partner of the signaling lymphocytic activation molecule-associated protein binding receptor CD229. J Immunol (2005) 0.96
CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo. Hepatology (2008) 0.95
Downregulation of proapoptotic proteins Bax and Bcl-X(S) in p53 overexpressing hepatocellular carcinomas. Biochem Biophys Res Commun (2000) 0.94
(-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis. Cancer Sci (2009) 0.93
Cutting edge: Ly9 (CD229), a SLAM family receptor, negatively regulates the development of thymic innate memory-like CD8+ T and invariant NKT cells. J Immunol (2012) 0.88
Dynamic expression of apoptosis-related genes during development of laboratory hepatocellular carcinoma and its relation to apoptosis. World J Gastroenterol (2005) 0.87
Piercing the armor of hepatobiliary cancer: Bcl-2 homology domain 3 (BH3) mimetics and cell death. Hepatology (2007) 0.86
The cell surface expression of SAP-binding receptor CD229 is regulated via its interaction with clathrin-associated adaptor complex 2 (AP-2). J Biol Chem (2003) 0.85
Calpain activation by hepatitis C virus proteins inhibits the extrinsic apoptotic signaling pathway. Hepatology (2009) 0.83
Isolation and characterization of cDNA clones for Humly9: the human homologue of mouse Ly9. Immunogenetics (1996) 0.82
Adenoviral delivery of recombinant DNA into transgenic mice bearing hepatocellular carcinomas. Hum Gene Ther (1996) 0.78